Biotech company Adcendo has announced the successful closing of an oversubscribed $135 million Series B financing round. Proceeds from the fundraise will be used to accelerate the development of the company's ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programmes. The financing round was led by TCGX, with participation […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!